Skip to Content
Merck
CN

Nonpungent N-AVAM Capsaicin Analogues and Cancer Therapy.

Journal of medicinal chemistry (2021-01-29)
Stephen D Richbart, Jamie R Friedman, Kathleen C Brown, Rama S Gadepalli, Sarah L Miles, John M Rimoldi, Gary O Rankin, Monica A Valentovic, Maria T Tirona, Paul T Finch, Joshua A Hess, Piyali Dasgupta
ABSTRACT

Capsaicin displays robust growth-inhibitory activity in multiple human cancers. However, the feasibility of capsaicin as a clinically relevant anticancer drug is hampered by its adverse side effects. This concern has led to extensive research focused on the isolation and synthesis of second-generation nonpungent capsaicin analogues with potent antineoplastic activity. A major class of nonpungent capsaicin-like compounds belongs to the N-acyl-vanillylamide (N-AVAM) derivatives of capsaicin (hereafter referred as N-AVAM capsaicin analogues). This perspective discusses the isolation of N-AVAM capsaicin analogues from natural sources as well as their synthesis by chemical and enzymatic methods. The perspective describes the pharmacokinetic properties and anticancer activity of N-AVAM capsaicin analogues. The signaling pathways underlying the growth-inhibitory effects of N-AVAM capsaicin analogues have also been highlighted. It is hoped that the insights obtained in this perspective will facilitate the synthesis of a second generation of N-AVAM capsaicin analogues with improved stability and growth-suppressive activity in human cancer.